| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1992051 | The Journal of Steroid Biochemistry and Molecular Biology | 2011 | 7 Pages |
Abstract
Steroid 5 alpha-reductase inhibitors (5ARIs) have been approved for use clinically in treatment of benign prostate hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) and have also been evaluated in clinical trials for prevention and treatment of prostate cancer. There are currently two steroidal inhibitors in use, finasteride and dutasteride, both with distinct pharmacokinetic properties. This review will examine the evidence presented by various studies supporting the use of these steroidal inhibitors in the prevention and treatment of prostate disease.Article from the Special issue on Targeted Inhibitors.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Lucy J. Schmidt, Donald J. Tindall,